Abstract | BACKGROUND: CASE PRESENTATION: A 73-year-old male with sigmoid colon cancer and synchronous lung metastasis was treated with panitumumab, an alone anti-EGFR monoclonal antibody as the third-line therapy.During the nine courses of the therapy, the response was stable disease (SD), but skin disorder gradually appeared obviously (CTCAE version 4.0: Grade 2). After 1 month of administration of Abound™, symptoms of the skin disorder improved (CTCAE version 4.0: Grade 1), thus the antibody therapy could be continued. CONCLUSION: We report that Abound™ was apparently effective in the treatment for anti-EGFR antibody-associated skin disorder. In the future, Abound™ could be expected as an agent for skin disorder as one of the side effects of colorectal cancer therapy.
|
Authors | Nobuhisa Matsuhashi, Takao Takahashi, Kenichi Nonaka, Kengo Ichikawa, Kazunori Yawata, Toshiyuki Tanahashi, Hisashi Imai, Yoshiyuki Sasaki, Yoshihiro Tanaka, Naoki Okumura, Kazuya Yamaguchi, Shinji Osada, Kazuhiro Yoshida |
Journal | World journal of surgical oncology
(World J Surg Oncol)
Vol. 12
Pg. 35
(Feb 11 2014)
ISSN: 1477-7819 [Electronic] England |
PMID | 24517087
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Dipeptides
- Valerates
- arginyl-glutamine
- beta-hydroxyisovaleric acid
- Panitumumab
- EGFR protein, human
- ErbB Receptors
|
Topics |
- Aged
- Antibodies, Monoclonal
(adverse effects)
- Colonic Neoplasms
(drug therapy, pathology)
- Dipeptides
(therapeutic use)
- ErbB Receptors
(antagonists & inhibitors, immunology)
- Humans
- Lung Neoplasms
(drug therapy, secondary)
- Male
- Panitumumab
- Prognosis
- Skin Diseases
(chemically induced, drug therapy)
- Valerates
(therapeutic use)
|